Honasa Consumer acquires 58% stake in Fluence Pharma to enter nutraceuticals
Honasa Consumer · Personal Products
Key highlights
- Honasa Consumer Limited acquired a majority 58% stake in Fluence Pharma on June 23, 2026.
- Fluence Pharma specializes in patented Cyclical Nutrition Therapy, with revenue ~₹40 crore and 20%+ EBITDA margin in FY26.
- Honasa will build a new subsidiary, Honasa Health, to scale Fluence’s nutraceutical portfolio leveraging digital and dermatology networks.
Why it's rated notable: The filing states a 58% majority stake but no purchase price, and Fluence's ~INR 40 Crore FY26 revenue is small against the company's ₹2,746 crore annual revenue, so the level is medium by default without an amount.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Honasa Consumer
- Acquisition / mergerNotableHonasa Consumer Ltd calls off proposed acquisition of Fluence Pharma Pvt Ltd
- Acquisition / mergerMajor developmentHonasa Consumer Limited announces audited FY26 results with unqualified audit opinion
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- EmamiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.